ADMA Biologics vs Alvotech
ADMA and ALVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and ALVO compare
Alvotech grew revenue faster over the last twelve months (19.7% versus 6.3% for ADMA Biologics).
ADMA Biologics scores higher on the StockData Score (16 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | ALVO |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | – |
| Share price | $13.24 | $4.67 |
| Change, 1 year | −17.4% | −16.3% |
| Change, 5 years | 765% | −52.9% |
| Beta (5Y) | 0.64 | 0.44 |
| Employees | 647 | 1,000 |
| StockData Score | ||
| Total score | 16 (better) | 3 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.2× | – |
| P/S | 5.7× | – |
| P/B | 6.8× | – |
| EV/EBITDA | 12.2× | – |
| P/FCF | 22.3× | – |
| FCF yield | 4.5% | – |
| Fair value | $21.15 | – |
| Margin of safety | 37.4% | – |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 19.7% (better) |
| Revenue growth, 5Y average | 64.6% (better) | 54.5% |
| Net income growth (TTM) | −12.9% | – |
| EPS growth (TTM) | −9.4% | – |
| Profitability | ||
| Gross margin | 68.5% (better) | 59.8% |
| Operating margin | 46.5% (better) | 13.3% |
| Net margin | 35.1% | – |
| FCF margin | 25.6% (better) | −19.6% |
| Return on equity | 41.9% | – |
| Return on invested capital | 39.4% | – |
| Financial health | ||
| Debt / equity | 0.45 | – |
| Net debt / EBITDA | 0.29 (better) | 10.02 |
| Interest coverage | 22.8× (better) | 0.5× |
| Current ratio | 6.04 (better) | 1.65 |
| Altman Z-score | 8.58 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% | – |
| Ownership | ||
| Held by institutions | 91.8% | – |
| Held by insiders | 3.0% | 67.7% |
| Insider net buying, 12 months | −$2.5M | – |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 8.3% | – |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- ALVO stock overview
- ALVO income statement
- ALVO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.